Clinical Trial for Evaluating the Effectiveness and Safety of the Pulse Wave-based Atrial Fibrillation and Premature Beat Alert Software

Inclusion criteria

• Patients over 18 years old, regardless of gender;
• Participants who meet one of the following conditions according to the medical history in the past 3 months or the ECG during the screening period:

• Patients with normal sinus rhythm;
• Patients with persistent or permanent paroxysmal atrial fibrillation or in the onset of paroxysmal atrial fibrillation;
• Patients with frequent premature beats (more than 5 per minute) or in the onset of premature beats;
• Patients who volunteer to participate and have signed an informed consent form.

Exclusion criteria

• Patients using cardiac pacemakers or implantable cardioverter defibrillators (ICD);
• Patients with non-respiratory sinus arrhythmia, sinus arrest or sick sinus syndrome according to the ECG results during the screening period;
• Patients with interpolated premature beats, junctional premature beats, or escape rhythms according to the ECG results during the screening period;
• Patients with atrial flutter, ventricular flutter, or ventricular fibrillation according to the ECG results during the screening period;
• Patients with atrial fibrillation or premature beats who have a resting heart rate of slower than 50 beats/minute or faster than 110 beats/minute according to the ECG results during the screening period;
• Patients who are critically ill, making it difficult to make an accurate assessment of the effectiveness and safety of the device;
• Patients who suffer from tremor diseases or chorea, making it difficult to complete the examination quietly;
• Patients with bullous diseases or large-area skin rashes that are not suitable for body surface electrode recording;
• Patients whose skin is allergic to ethanol;
• Patients with contagious skin diseases;
• Patients with tattoos on their wrist skin that is to be measured;
• Patients with poor compliance who are unable to cooperate to complete this investigation on their own;
• Patients who have participated in other clinical investigations within the past 30 days that may affect this investigation;
• Other conditions that the investigators consider inappropriate for participation in the investigation.